Drug profile

The FDA adverse-event record for Leptospirosis Vaccination

14 FDA reports name Leptospirosis Vaccination, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2178 of 2,679
by report volume (all drugs)
14
adverse-event reports
14.3%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Leptospirosis Vaccination ranks #2133 of 2679 by total reports (14). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2133
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Leptospirosis Vaccination has 14 reports now versus 14 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Leptospirosis Vaccination changes

Signature read: 14 reports place Leptospirosis Vaccination in the lower third of FDA AER volume (#2178 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
2
Deaths Reported
14.3%
Death-coded share of reports

Active Ingredients

Leptospirosis Vaccination

Administration Routes

UnknownSubcutaneous

Species Affected

Dog 14

Most Affected Breeds

Retriever - Golden 2
Spitz - German Pomeranian 2
Pit Bull 1
Poodle - Toy 1
Chihuahua 1
Retriever - Labrador 1
Boxer (German Boxer) 1
Siberian Husky 1
Dog (unknown) 1
Bloodhound 1

Most Reported Reactions

Vomiting 4
Lethargy (see also Central nervous system depression in 'Neurological') 2
Death by euthanasia 2
Decreased appetite 2
Diarrhoea 2
Collapse NOS (see also 'Cardio-vascular' and 'Neurological disorders') 1
Implant site abscess 1
Inappetence 1
Hyperthermia 1
Reluctant to move 1
Muscle weakness NOS 1
Constipation 1

Outcome Breakdown

Recovered/Normal
10 (71.4%)
Euthanized
2 (14.3%)
Recovered with Sequela
1 (7.1%)
Ongoing
1 (7.1%)

Leptospirosis Vaccination: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Leptospirosis Vaccination (#2178 of 2,679 by report volume); death-coded 14.3%. PlainBreed drug row · report volume stamp 14 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →